MedTrace Logo

Oral Green Tea Extract for Small Cell Lung Cancer

NCT01317953 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-04-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether green tea extract is safe for extensive-stage small lung cancer who achieved objective tumor response after first-line therapy.

Conditions

  • Small Cell Lung Carcinoma

Interventions

DIETARY_SUPPLEMENT

epigallocatechin gallate

Starting dose green tea catechin extract "EGCG" 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    lead OTHER

Principal Investigators

  • Xindong Sun, M.D. · Shan Dong Tumor Hospital and Institute

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317953 on ClinicalTrials.gov